AstraZeneca: new failure for Fasenra in COPD
(CercleFinance.com) - AstraZeneca and its subsidiary MedImmune have announced disappointing results for Terranova, the second of two pivotal phase III trials for Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD).
The trial did not achieve its primary endpoint of a statistically significant reduction in exacerbation. A complete evaluation of data is currently underway and the results will be presented at a future scientific meeting.
Adding that its first pivotal test Galathea also failed to achieve its primary endpoint, the British pharmaceutical company does not currently plan to make any filings with regulatory authorities.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The trial did not achieve its primary endpoint of a statistically significant reduction in exacerbation. A complete evaluation of data is currently underway and the results will be presented at a future scientific meeting.
Adding that its first pivotal test Galathea also failed to achieve its primary endpoint, the British pharmaceutical company does not currently plan to make any filings with regulatory authorities.
Copyright (c) 2018 CercleFinance.com. All rights reserved.